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IGRTa b s t r a c t
Purpose: This study aims to quantify the incidence and distribution of prostatic calculi in a population of
prostate radiotherapy patients and assess their potential role in prostate image guided radiotherapy
(IGRT).
Methods & materials: A retrospective analysis of trans-rectal ultrasound (TRUS), computed tomography
(CT) planning and treatment verification cone beam CT (CBCT) scans from radical prostate radiotherapy
patients (external beam and brachytherapy) between 2012 and 2014 was undertaken by a single expe-
rienced observer. An internationally validated schema from the Prostate Imaging Reporting and Data sys-
tem (PIRADS) was used to map the location of calculi. The association of calculi with patient and disease
characteristics was explored. Data was analysed using SPSS (IBM version 22.0) using descriptive statisti-
cal methods and logistic binary regression analysis.
Results: 389 scan sets from 254 patients were included in the analysis. The overall incidence of calculi
was 85% (n = 218) of which 79% (n = 201) were intra-prostatic calculi. The mean number of intra-
prostatic calculi was 2 (range 1–10) and the mean size of calculi was 3.7 mm (range 0.5–15 mm).
Calculi were most frequently observed in the posterior of the mid-gland (PI-RADs 3p, 9p) and posterior
of the apex (PI-RADs 5p, 11p). 99% (n = 135) of CT planning scans with a corresponding CBCT had calculi
in the same PIRADs location and all calculi were visible at the last fraction. There was no statistically sig-
nificant association of calculi and N stage, M stage or Gleason score.
Conclusions: A significant proportion of prostate radiotherapy patients have prostatic calculi detectable
on pre radiotherapy imaging. Calculi observed on CT were also detectable on CBCT in 99% of cases and
remain visible at the end of treatment. These findings add to the growing evidence base supporting
the potential of calculi as an alternative to fiducial markers to aid prostate IGRT.
Crown Copyright  2019 Published by Elsevier B.V. on behalf of European Society for Radiotherapy &
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction & background
Prostate cancer (PCa) is the most common cancer in men in the
UK and approximately half of patients diagnosed will receive
radiotherapy alone or in conjunction with surgery or hormone
therapy as part of their disease management [1]. Despite the rapid
evolution of imaged guided radiotherapy (IGRT), verification of soft
tissue targets like the prostate gland, remains challenging and
image analysis is prone to uncertainty and inter-observer variabil-
ity [2,3]. IGRT for PCa frequently employs surgically implanted
fiducial markers (FMs) as an aid to target verification. While theyare not used universally they are an evidence based approach [4]
and are recommended in a current clinical trial comparing surgery
and stereotactic ablative radiotherapy (SABR) for PCa (PACE trial
ISRCTN1762721).
FM insertion requires a surgical procedure prior to radiotherapy
planning. A suitable non-invasive alternative to FMs for prostate
IGRT would eliminate the need for this surgical intervention, the
risk of infection, bleeding and also the associated costs and
resources required.
Prostate calcifications, hereafter referred to as calculi, are small
round, ovoid or irregular structures which can develop in the pros-
tate gland and are frequently observed in prostatectomy speci-
mens [5]. They are often asymptomatic and their role in
prostatitis, benign prostatic hyperplasia, lower urinary tract symp-
toms and prostate cancer (PCa) is unclear. A recent paper by Venyo
et al. [6] provides a review of the literature in relation to calculi.
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There is a growing body of evidence suggesting that radiologi-
cally visible calculi could replace FMs as an aid to image analysis
in IGRT. Calculi visible on CBCT have been investigated and pro-
posed [7–9], while others have used them as valid reference points
in the assessment of image registration methods [10–12].
Harnessing calculi as IGRT markers may have significant bene-
fits for individual patients in terms of eliminating an invasive pro-
cedure and risk of infection. It may also have a significant impact
on health budgets depending on how many patients present with
calculi.
The reported incidence of calculi varies widely depending on
the method of detection. A study by Suh et al detected calculi in
almost 90% [5] of prostatectomy specimens. In contrast, the inci-
dence is reported as 35% [7] of prostate radiotherapy patients
based on the review of 131 cone beam computed tomography
(CBCT) images [7].
The purpose of this study was to establish the radiological inci-
dence and location of calculi in a contemporary population of pros-
tate radiotherapy patients. The association of calculi with patient
and disease characteristics was also explored.Fig. 1. Prostate Imaging and Reporting Data System (PI-RADS). Reproduced from
Dickinson et al., European Urology 59, 477–494, 2011 [13].Methods
Image review
Two hundred and fifty four PCa patients treated with radical
radiotherapy to the prostate or prostate and pelvis (external
beam and/or brachytherapy) between 2012 and 2014 were
included in this study. An experienced single-observer analysed
available trans-rectal ultrasound (TRUS) brachytherapy volume
study scans, radiotherapy planning CT scans and treatment verifi-
cation CBCT scans for the presence of calculi. To assess TRUS as a
modality for the detection of PC, we included brachytherapy TRUS
images since TRUS biopsy scans are not routinely archived at our
institution and therefore not available for retrospective evalua-
tion. TRUS scans were assessed using Variseed v8.0.2 (Varian
medical Systems). CT planning scans acquired at 2.5 mm slices
were reviewed in Centricity Web v3.0.10 (GE Medical Systems).
CBCTs of patients with calculi identified on planning CT were
reviewed to determine if CBCT detection of calculi is comparable
to that detected by CT. CBCTs were acquired on a Varian True-
beam using standard pelvis mode (kVp 125, mA 80, reconstructed
to 2 mm slices). CBCTs were assessed in Aria Off-Line review
using pelvic windowing.Data collection
A study pro-forma was designed for the purpose of data collec-
tion. This incorporated a diagrammatic schema from the Prostate
Imaging and Reporting Data system (PI-RADsTM Version 1.0) (see
Fig. 1). This schematically divides the prostate into 27 sections
and was used to map the distribution of calculi within the prostate
gland. Calculi were recorded when 1 or more were easily identified
within the prostate gland (intra-prostatic) or extra-prostatic but
close to the prostatic capsule and visible in the 3 cardinal planes.
The maximum axial dimension of the largest calculi was measured
using the software in each of the aforementioned applications.
In addition to data on the presence, size and location of calculi,
patient and disease characteristics were extracted and recorded
from patients medical histories including patient age, stage, initial
prostate specific antigen (iPSA) and Gleason score. Analysis of mag-
netic resonance images (MRI) was ruled out early in the study due
to the inability to differentiate possible calculi from blood productson images acquired using standard MRI protocols at our
institution.
Data analysis
Data was coded and analysed in SPSS (IBM version 22.0). Simple
descriptive statistical methods were used to describe the inci-
dence, size and distribution of calculi. Logistic binary regression




Incidence, distribution and size of calculi
389 scan sets (73 TRUS, 180 CT planning, 136 CBCT) from 254
patients were included in the analysis.
The overall incidence of patients with calculi (intra and extra-
prostatic) recorded across all imaging modalities was 85%
(n = 219). Limiting this to those patients presenting with intra-
prostatic calculi (with or without extra-prostatic calculi) reduced
this to 79% (n = 201). The mean number of intra-prostatic calculi
observed within a patient was 2 (range 1–10). The mean size (max-
imum axial diameter) of calculi observed was 3.7 mm (range 0.5–
15 mm). Calculi were most frequently observed in areas 3p and 9p
(posterior portion of the mid-gland) and also 5p and 11p (post por-
tion of the apex). Calculi were least often observed in 8a, 12a &
Table 1
Study Population.





6 N = 50
7 N = 94
8 N = 36
9 N = 69
10 N = 2
Missing N = 3
Clinical Disease Stage
T0-T1c N = 28
T2 N = 79
T3 N = 132
T4 N = 8
Missing 7
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calculi recorded according to their PIRADs location is shown in
Fig. 2.TRUS calculi and CT calculi (see Fig. 3)
TRUS scans from 73 brachytherapy patients were analysed of
which 64 patients (88%) had calculi visible. Of these 64, 49 had a
seed implant and 15 had no seed implant. 1 of the patients without
implant proceeded to prostatectomy. The remaining 14 patients,
following initial referral for brachytherapy, were subsequently
deemed unsuitable for implant due to larger than predicted pros-
tate volume. These 14 had a subsequent CT scan for EBRT of which
10 (71%) had calculi in the same PIRADs location as detected on
TRUS. The 49 patients with implant also had a corresponding CT
but meaningful comparison was difficult due to significant seed
artefact. Despite this 18 (37%) CT scans with seed implant had cal-
culi discernible. Nine patients TRUS demonstrated no calculi. One
of these 9 with seed implant presented with calculi on subsequent
CT.
























Fig. 2. The total number of intra-prostatic calculi recorded was 695. PIRADs location 3p
13.8%, respectively.CT calculi & CBCT calculi
CT planning scans from 180 patients were analysed of which
154 (86%) had calculi detected. 136 of the 154 with calculi had a
corresponding CBCT. 135/136 (99%) had calculi observed within
the same PIRADs section. 1 patient in the CT group without a cor-
responding treatment verification CBCT had widespread pelvic cal-
cification including multiple intra and extra prostatic calculi. These
were visible on an anterior 2DkV image however not clearly seen
on the lateral 2D kV image.
Calculi and disease characteristics
A binary logistic regression test was used in univariate and mul-
tivariate analysis to investigate the associations between different
variables and the presence of calcifications as observed on CT. (See
Table 2) The incidence of calculi was positively correlated with age,
PSA and increasing T stage and negatively correlated with increas-
ing N stage, but none were found to be statistically significant. Uni-
variate analysis revealed that the odds ratio (OR) of having
calcifications increase by a factor 1.2 per unit increase in Gleason
score and decrease by 2% for increase in N stage. However, a step
wise regression showed that after adjusting for N and M stages
none of the investigated variables were significantly associated
with the presence of calcifications.
Discussion
To our knowledge this is the first study to report the radiologi-
cally detected incidence of prostatic calculi using an internation-
ally validated anatomical mapping schema. The incidence of
prostatic calculi in our sample of 254 radical prostate radiotherapy
patients was 85%. Where present the average number of calculi per
patient was 2 and the average size 3.7 mm. They were most fre-
quently observed in the posterior of the apex and mid-gland and
least frequently in the anterior base and apex.
These results are in-line with Suh et al. [5] who report the
incidence to be 88.6% (264/298) of prostatectomy specimens.
The incidence in our sample is considerably higher than the
35% reported by Zeng et al. [7] from a review of 131 prostate
radiotherapy CT planning scans. One possible reason for the dif-
ference might be that we did not pre-define calculi size criteria.
Zeng et al. [7] set a size criteria of >2 mm in diameter for a calculi Locaon
and 9p (posterior mid gland) exhibited the highest frequency of PC of 14.9% and
73 TRUS 
(brachytherapy)
64 paents with PC 
visible on TRUS









10 (71%) PC 
at CT 
planning scan






9 without PC on TRUS (all 
with seed implant)
1 with PC at 
brachy CT 
veriﬁcaon
Fig. 3. Schematic to show TRUS PC and subsequent CT PC.
Table 2






Gleason 1.246 (1.026–1.513) 0.027 1.205 (0.981–1.480) 0.076
N 0.980 (0.962–0.998) 0.029 0.991 (0.961–1.022) 0.580
M 0.977 (0.962–1.001) 0.066 0.988 (0.951–1.027) 0.546
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dose CBCT, but may have eliminated a significant number of
smaller yet visible calculi. More recently Hama et al. [14] report
the highest incidence from a radiological study of 93% of 30
patients detected on kVCT. They defined calculi criteria based
on at least 2 pixels equating to 1.9 mm2. In our study we did
not predefine criteria adopting the pragmatic approach that if a
calculi could be visualised then it could also be contoured and
therefore potentially used to aid IGRT. In our study 135 out of
136 planning CT scans with calculi had corresponding calculi on
CBCT. The calculi not subsequently detected on CBCT had a max-
imum diameter of 1.5 mm axially. In total there were 39 calculi
detected measuring 2 mm or less. One sub millimetre calculi
was visible on the anterior view of the CBCT but not on the lateral
view. These observations suggest that factors other than size
affect radiological calculi detection. Such factors may include,
imaging parameters, day to day variations in CBCT quality, image
artefact, patient specific variations such as rectal gas or patient
size, and variations in the density and radio-opacity of individual
calculi. Notably, calculi were present at the beginning and end of
treatment demonstrating that, at least for the duration of treat-
ment, their presence appeared unaffected by radiation.
One of the largest and most recent studies of calculi was
reported by Park et al. [15] who found that 76.6% of TRUS scans
from 606 patients demonstrated calculi supporting the idea that
they are a very common phenomenon.The role of IGRT in ensuring adequate dose coverage of the pros-
tate and avoidance of the rectal wall is well documented [16–19].
In this study calculi were most frequently observed in the posterior
portion of the gland. This aligns with one of the earliest reports on
prostatic calculi [20]. These calculi may have a particular relevance
for prostate IGRT providing a marker at the prostate/rectal inter-
face where planning margins are often reduced to minimise rectal
toxicity. Location may prove to be even more significant if proven
to be linked to PCa or even foci of PCa within the prostate as sug-
gested by Smolski et al. [21]. In this scenario the calculi might actu-
ally become the target, or surrogate, for an intra-prostatic boost.
There are a number of limitations inherent in our study. TRUS
biopsy images are not routinely acquired at our institution there-
fore this analysis was limited to the use of brachytherapy images.
18 out of 49 patients with seed implant in our patient cohort had
calculi visible on CT. There may have been more that were
obscured by seed artefact therefore it’s not possible to draw any
sound conclusion on the correlation of TRUS calculi with CT calculi
from this group. However, 71% of patients with calculi on TRUS had
corresponding calculi on CT based on the 14 patients without
implant, indicating that even in this small sample TRUS is not reli-
able for predicting calculi on CT. Another weakness is of course
that this was a retrospective analysis and therefore selection bias
cannot be completely ruled out.
While not the primary focus of this study, the authors believed
it pertinent to provide a brief analysis of calculi in relation to any
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exist that calculi may be associated with increasing age, disease
stage, Gleason score or other characteristics [5,22,23]. Suh et al.
[5] reported a linear correlation of calculi incidence and age. In this
study also calculi incidence is associated with increasing age how-
ever this was not statistically significant. (p = 0.08) Our data sug-
gested that the presence of calculi were more likely with
increasing Gleason score and less likely with nodal stage. However,
on multivariate analysis neither association was statistically
significant.Issues for clinical implementation of prostate calculi guided IGRT
The correlation of calculi detectable on pre-treatment CT plan-
ning scans and subsequently on CBCT scans is important in order to
establish that calculi can be detected by both imaging modalities.
In our sample this was found to be the case in 99% of patients. In
a centre, such as ours, where FMs are not routinely employed, cal-
culi could be used for prostate IGRT by simply identifying them at
CT planning. If they are then also visible on CBCT, which our data
suggest they are, then they may be used to enhance existing pros-
tate IGRT protocols as a recognised reference structure for image
analysis. Should the case occurs that calculi are not visible on CBCT
then standard bony anatomy and soft tissue registrations may be
the default.
For those centres where prostate FMs are standard the ability to
correlate TRUS detection of calculi with pre-treatment CT and CBCT
is key. In this scenario it would be necessary to identify with a high
degree of success patients whose calculi could substitute FMs.
TRUS biopsy may present an opportunity to assess calculi status.
However TRUS detection of calculi not then detectable on CT, as
demonstrated in 4 out of 14 patients in this study for example,
may result in a patient receiving non-marker based treatment or
a introduce a delay in treatment starting to facilitate FM insertion.
Ideally calculi would be detected at MRI staging. This may be pos-
sible in the future as multi-parametric MR (mpMRI) becomes more
widely practiced. Susceptibility weighted imaging (SWI) is one
example where mpMRI may assist in the diagnosis of PCa and
has been shown to be as effective as CT in detecting calculi [24].
In addition to the timely detection of calculi, the number of cal-
culi is also relevant to consider if they are to replace FMs. Two or
three FMs, depending on length and separation, have been sug-
gested as adequate to assess the position of the prostate [25]. Other
factors are relevant in relation to this such as the imaging modality
used and as previously mentioned, the location. Three markers
may be preferable when using 2D imaging but when used in con-
junction with 3D imaging, fewer markers and therefore calculi may
provide a viable reference point. Some evidence exists suggesting
that the existence of 1 or more calculi improves the accuracy of
prostate CT/CBCT image registrations [11], however to date a direct
comparison of calculi with FMs has not been reported.
As stereotactic radiotherapy for prostate cancer becomes more
widely available, so too the need for ensuring accuracy in treat-
ment delivery with currently available imaging technology. It is
likely the use of FMs will increase and this will have a real impact
on local health budgets. Calculi present a potential non-surgical
alternative to FMs in a significant proportion of patients. Despite
the incidence of calculi and the growing evidence base for their
role in IGRT, more robust comparison directly with FMs in larger
cohorts of patients is required.Conclusions and future work
The PIRADs schema proved an invaluable tool, providing a con-
sistent and reproducible way to report the location of calculi. Theincidence of calculi was positively correlated with age, PSA and
increasing T stage and negatively correlated with increasing N
stage, but none were found to be statistically significant. Correla-
tion of TRUS calculi and CT calculi was not completely reliable.
In this study, a significant proportion (85%) of patients with PCa
have calculi detectable on pre-radiotherapy imaging and 99% of
those detected on CT were subsequently detected on CBCT and
remained visible at the end of a course if radiotherapy. This sup-
ports the use of calculi as a possible alternative to FMs for prostate
IGRT.
A prospective clinical trial is underway at our institution evalu-
ating calculi for IGRT image analysis and the clinical feasibility of
such an approach for localised prostate cancer patients. All patients
within the trial have FMs implanted and receive daily CBCT FM
marker guided treatment. A comprehensive analysis of daily
CBCTs, treatment set-up accuracy and planning margins based on
data from FMs and calculi, were present, will be directly compared
within each patient. The study will incorporate PI-RADsTM Version
2.0 [26] and a prospective radiological analysis of prostatic calculi
in TRUS, CT and CBCT.Conflict of interest declaration
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